A phase 2 study showed a 93.3% objective response rate for lenvatinib and tislelizumab in FH-RCC patients, with a 20% complete response rate. FH-RCC is driven by FH gene mutations, leading to ...

Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC ...

Count Me In, a patient-partnered research initiative led by the Broad Institute of MIT and Harvard and Dana-Farber Cancer ...

Compared with other ablative therapies, stereotactic body radiotherapy might offer a ‘particularly advantageous option’ for ...

Renal cell carcinoma is the most common form of kidney cancer. It can take time to fully process a diagnosis and what, exactly, it may mean.

Count Me In, a patient-partnered research initiative led by Dana-Farber Cancer Institute and the Broad Institute of MIT and ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

NSAID use was not associated with an increased risk of death among men with RCC. The use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of death in women ...